ClinicalTrials.gg
Not yet recruitingNCT06998771Updated May 31, 2025

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

A Phase 2 interventional study of JSKN003 and KN026 in HER2-positive Gastric Cancer, sponsored by Shanghai JMT-Bio Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.

02

Conditions studied

  • HER2-positive Gastric Cancer

Browse trials for

03

In context

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

This study's planned enrollment of 153 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Shanghai JMT-Bio Inc. is the lead sponsor of 42 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18 years old.
  • or cytologically confirmed diagnosis of gastric cancer.
  • The population enrolls participants with -positive unresectable locally advanced or gastric cancer who had not received systemic treatment, and Perioperative population enrolls participants with HER2-positive resectable gastric cancer who had not received treatment.
  • HER2-positive (defined as IHC3+ or IHC 2+/FISH +).
  • The first-line population: presence of at least 1 per 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • PS of 0 - 1.
  • Expected survival ≥ 3 months.
  • Participants with adequate organ functions.
  • Female and male patients of childbearing age agree to take adequate measures during and upon completion of the study for 7 months after the last dose. Female participants of childbearing age must have a negative blood pregnancy test within 7 days before the first dose or randomization.
  • Voluntarily agree to participate in the study and sign the .

Exclusion criteria

Exclusion Criteria:

  • Has received anti-tumor treatment such as systemic chemotherapy or other trial interventions within 28 days, or immunotherapy (e.g. interleukin, interferon, thymospipeptide, etc.), hormone therapy or targeted therapy within 14 days or 5 half-life (whichever is shorter) before the first dose or randomization.
  • Has previously been treated with an anti- ADC loaded with topoisomerase I inhibitors.
  • Participants with or spinal cord compression at screening (except for completed local treatment and discontinued for at least 4 weeks before the first dose or randomization , and stable central nervous system imaging and brain metastasis symptoms for at least 4 weeks).
  • Participants with CPS ≥1, who are receiving long-term immunotherapy (e.g., cyclosporine) or require daily systemic steroid therapy (e.g., >20 mg prednisone or equivalent), except those who treated with local glucocorticoids using nasal spray, inhalation, or other pathways.
  • Participants with PD-L1CPS ≥1, who have an active disease or have a history of autoimmune disease 2 years before the first dose or randomization and still require systemic treatment. However, participant with the following diseases is allowed to enroll: well-controlled type I diabetes, well-controlled hypothyroidism that requires hormone replacement therapy, skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss), or participant who is expected to not recur without external triggers.
  • Participate in another clinical trial, unless it is an observational (non-intervention) clinical trial or is in the follow-up period of an intervention trial.
  • Participants who have undergone major surgery or had invasive intervention within 28 days before the first dose or randomization. Or those who plan to undergo systematic or local tumor resection during the trial (Perioperative cohort does not apply).
  • Any Chinese patent medicine with anti-cancer activity approved by the National Drug Administration (regardless of cancer type) has been used within 14 days before the first dose or randomization.
  • Has a history of severe reactions to either the drug substances or inactive ingredients in the drug product.
  • Active bacterial, fungal or viral infection before the first dose or randomization. Participant who has recieved preventive infection treatment but has no clinical manifestations before the first dose or randomization could be considered to enroll.
  • Has a history of immunodeficiency, including -positive.
  • Active or C infection. Participant with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) need to test Hepatitis B virus DeoxyriboNucleic Acid (HBV-DNA), and HBV-DNA is higher than 500 IU/mL (or 2500 copies/ml) or (UNL) (whichever is lower) ; Participants with positive for (HCV) antibody and whose Hepatitis C virus Ribonucleic Acid (HCV-RNA) is higher than 1000 copies/ml or UNL (whichever is lower).
  • Has a history of tuberculosis treatment within 2 years before the first dose or randomization.
  • Has activity or a history of interstitial lung disease at any stage and/or pulmonary function injury, a history of interstitial pneumonia requiring hormone therapy, or the imaging cannot rule out suspected interstitial lung disease/pneumonia at screening.
  • Known to have low activity or lack of dihydropyrimidine dehydrogenase (DPD).
  • Participants with peripheral neuropathy of grade > 1.
  • Participants with gastrointestinal diseases including but not limited to severe liver diseases, ulcerative colitis, inflammatory bowel disease and other gastrointestinal diseases 28 days before the first dose or randomization.
  • Has a history of severe cardiovascular disease.
  • History of any other malignant tumors within 5 years before the first dose or randomization.
  • within 28 days before the first dose or randomization. Note: Seasonal influenza vaccine is a broadly inactivated vaccine and is allowed to be used;
  • Unable to swallow orally, or there are conditions that have been judged by researchers to seriously affect gastrointestinal absorption (such as severe Crohn's disease, malabsorption syndrome, etc.).
  • Pregnant or breastfeeding women.
  • Otherwise considered inappropriate for the study by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
153 participants (estimated)

Study arms

  • Experimental
    Combination of JSKN003 and capecitabine with or without enlonstobart

    Drug: JSKN003 · Drug: Capecitabine · Drug: Enlonstobart

  • Experimental
    Combination of JSKN003, capecitabine and KN026 with or without enlonstobart

    Drug: JSKN003 · Drug: KN026 · Drug: Capecitabine · Drug: Enlonstobart

  • Experimental
    Combination of JSKN003, capecitabine and oxaliplatin with or without enlonstobart

    Drug: JSKN003 · Drug: Capecitabine · Drug: Enlonstobart · Drug: Oxaliplatin

  • Experimental
    Combination of trastuzumab, capecitabine and oxaliplatin with or without pembolizumab

    Drug: Capecitabine · Drug: Oxaliplatin · Drug: Trastuzumab · Drug: Pembolizumab

Interventions

  • JSKN003 is administered by intravenous infusion.

  • DrugKN026

    KN026 is administered by intravenous infusion.

  • Capecitabine is for oral administration.

  • Enlonstobart is administered by intravenous infusion.

  • Oxaliplatin is administered by intravenous infusion.

  • Trastuzumab is administered by intravenous infusion.

  • Pembolizumab is administered by intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) of the first-line population

    Time frame: Frame: Up to approximately 5 years

  2. Incidence and severity of TEAE and SAE of the first-line population

    Time frame: Up to approximately 5 years

  3. pCR rate after neoadjuvant therapy of perioperative population

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Disease Control Rate (DCR) of the first-line population

    Time frame: Up to approximately 5 years

  2. Duration of Response (DoR) of the first-line population

    Time frame: Up to approximately 5 years

  3. Progression-free survival (PFS) of the first-line populations

    Time frame: Up to approximately 5 years

  4. Major pathological response (MPR) rate of perioperative population

    Time frame: Up to approximately 5 years

  5. R0 rate of perioperative population

    Time frame: Up to approximately 5 years

  6. Event-free survival (EFS) of perioperative population

    Time frame: Up to approximately 5 years

  7. Overall Survival (OS)

    Time frame: Up to approximately 5 years

  8. Incidence and severity of AE

    Time frame: Up to approximately 5 years

  9. Blood concentration of JSKN003

    Time frame: Up to approximately 2 years

  10. Blood concentration of total antibodies for JSKN003

    Time frame: Up to approximately 2 years

  11. Blood concentration of free toxins for JSKN003

    Time frame: Up to approximately 2 years

  12. Serum concentration of KN026

    Time frame: Up to approximately 2 years

  13. Serum concentration of Enlonstobart;

    Time frame: Up to approximately 2 years

  14. Anti-drug antibodies (ADA) related to JSKN003

    Time frame: Up to approximately 2 years

  15. Title: ADA related to KN026

    Time frame: Up to approximately 2 years

  16. ADA related to Enlonstobart

    Time frame: Up to approximately 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Jun 2028, 36 months later.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 36 months is close to that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
May 31, 2025
StartEst.
Jun 15, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2029
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06998771
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Jun 15, 2025 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anbenitamab repodatecan · Anbenitamab · Enlonstobart

Start the discussion